Download these real-world MAVENCLAD patient case studies provided by healthcare providers from around the world.
Learn about a busy, young mother switching from an injectable treatment
DOWNLOAD NOW
Learn about a male patient with progressed disease who is switching from an oral treatment
DOWNLOAD NOW
Learn about a female patient switching from an oral treatment and considering having another child after 20 months
DOWNLOAD NOW
Learn about a female patient who cannot adhere to her previous oral treatment due to side effects
DOWNLOAD NOW
WARNING: MALIGNANCIES and RISK OF TERATOGENICITY
CONTRAINDICATIONS
WARNINGS AND PRECAUTIONS
Adverse Reactions: The most common adverse reactions with an incidence of >20% for MAVENCLAD are upper respiratory tract infection, headache, and lymphopenia.
Drug Interactions/Concomitant Medication: Concomitant use of MAVENCLAD with immunosuppressive or myelosuppressive drugs and some immunomodulatory drugs (e.g., interferon beta) is not recommended and may increase the risk of adverse reactions. Acute short-term therapy with corticosteroids can be administered.
Avoid concomitant use of certain antiviral and antiretroviral drugs. Avoid concomitant use of BCRP or ENT/CNT inhibitors as they may alter bioavailability of MAVENCLAD.
Use in Specific Populations: Studies have not been performed in pediatric or elderly patients, pregnant or breastfeeding women. Use in patients with moderate to severe renal or hepatic impairment is not recommended.
Please see the full Prescribing Information, including boxed WARNING for additional information.
MAVENCLAD® (cladribine) tablets is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include relapsing-remitting disease and active secondary progressive disease, in adults. Because of its safety profile, use of MAVENCLAD is generally recommended for patients who have had an inadequate response to, or are unable to tolerate, an alternate drug indicated for the treatment of MS.
Limitations of Use: MAVENCLAD is not recommended for use in patients with clinically isolated syndrome (CIS) because of its safety profile.
WARNING: MALIGNANCIES and RISK OF TERATOGENICITY
CONTRAINDICATIONS
WARNINGS AND PRECAUTIONS
Adverse Reactions: The most common adverse reactions with an incidence of >20% for MAVENCLAD are upper respiratory tract infection, headache, and lymphopenia.
Drug Interactions/Concomitant Medication: Concomitant use of MAVENCLAD with immunosuppressive or myelosuppressive drugs and some immunomodulatory drugs (e.g., interferon beta) is not recommended and may increase the risk of adverse reactions. Acute short-term therapy with corticosteroids can be administered.
Avoid concomitant use of certain antiviral and antiretroviral drugs. Avoid concomitant use of BCRP or ENT/CNT inhibitors as they may alter bioavailability of MAVENCLAD.
Use in Specific Populations: Studies have not been performed in pediatric or elderly patients, pregnant or breastfeeding women. Use in patients with moderate to severe renal or hepatic impairment is not recommended.
Please see the full Prescribing Information, including boxed WARNING for additional information.
Health Care Professional Update for COVID-19: We understand there is a high level of uncertainty related to the novel coronavirus (COVID-19) situation. At EMD Serono, we are taking the COVID-19 situation seriously and are committed to those living with MS and delivering meaningful solutions that help address therapeutic needs of individual patients. In addition to public health guidance issued by local medical or patient associations, more information about COVID-19 can be found on the Centers for Disease Control’s (CDC) website or the World Health Organization’s website. For any questions about COVID-19 in relation to EMD Serono products, please contact Medical Information at +1-888-275-7376.
Help us direct you to the right place by selecting one of the following options:
The content on this website is intended for U.S. Healthcare Professionals. By entering this website, you confirm you are a U.S. Healthcare Professional.
The content on this website is intended for U.S. Healthcare Professionals only. For more information, click CONTINUE to visit the consumer website.